RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today announced that data from preclinical studies of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in poster sessions at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, October 31-November 4, 2008.
